You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Cost-effectiveness ratio under different circumstances and at different ages of vaccination

From: Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands

  60 years* 65 years 70 year 75 years 80 years
Base case €38519 €31228 €21716 €24336 €34449
No prevention of death €38901 €31489 €21910 €25020 €35930
No daytime visits hospital €38540 €31251 €21731 €24351 €34458
No discounting €33305 €27482 €18827 €21688 €31285
Discounting 3.5%/3.5% €45313 €36210 €25647 €27874 €38725
Vaccine price €60 per dose €30045 €24658 €17163 €19228 €27304
Vaccine price €50 per dose €25061 €20793 €14485 €16224 €23100
Application costs €9.60** €40911 €33083 €23002 €25778 €36466
Duration protection 4.8 years*** €61247 €48828 €27817 €32449 €42428
Duration protection 16.1 years*** €16954 €15031 €14030 €16013 €25953
  1. * indirect costs included (loss of working hours, only relevant for vaccination at 60 years of age)
  2. ** full influenza tariff (instead of half the influenza tariff €4.80, that was used in the base case)
  3. *** based on van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27(9):1454-67.